InventageLab Begins Dosing for Long-Acting Dementia Treatment Phase 1 and 2 Trials in Australia

Inventage Lab announced on the 28th that it has officially commenced Phase 1 and 2 clinical trials of the long-acting injectable drug 'IVL3003' for dementia treatment in Australia.

Exterior view of Inventage Lab research center [Photo by Inventage Lab]

The trial entered its main phase as drug administration to the first subject took place on the 27th. The plan is to evaluate the safety and pharmacokinetic/pharmacodynamic properties of IVL3003 in 42 healthy individuals. The subjects will be divided into three groups, with increasing doses administered via subcutaneous injection, while an oral marketed drug will be given to the control group.

Through this Phase 1 and 2 trial, Inventage Lab aims to demonstrate the sustained drug release characteristics of IVL3003, which were confirmed in preclinical studies, and to determine the optimal dosage by the first half of 2024.

IVL3003 incorporates Inventage Lab’s proprietary 'IVL-DrugFluidic' technology, which controls the initial burst release of the drug and maintains a stable blood concentration over the target period. It is expected to improve patient and healthcare provider satisfaction by addressing common issues of existing dementia treatments such as low medication adherence, potential gastrointestinal side effects, and dysphagia (swallowing difficulties).

Joohee Kim, CEO of Inventage Lab, stated, “We plan to confirm the superior pharmacokinetics of the sustained-release injectable formulation compared to oral formulations in this clinical trial,” adding, “We expect this to be an opportunity to prove the safety and efficacy of IVL3003 and to confirm its potential as a ‘Best-in-Class’ dementia treatment.”

This content was produced with the assistance of AI translation services.